Milestone Scientific, Inc. Reports Progress Related to its Exclusive Distribution Agreement with Henry Schein, Inc.
Henry Schein Ahead of Schedule in Training its Exclusive Products Sales Specialists on The Wand(R) STA Single Tooth Anesthesia System(R) Instrument
LIVINGSTON, NJ -- (Marketwired) -- 12/08/16 -- Milestone Scientific Inc . (NYSE MKT: MLSS), a medical R&D and dental products company that designs, patents, incubates and commercializes a growing portfolio of innovative therapeutic injection technologies, today provided an update related to its Wand Dental, Inc subsidiary, and its recently announced ten-year exclusive distribution agreement with Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners for The Wand® STA Computer Assisted Anesthesia System.
Since announcing the agreement, Henry Schein has completed ahead of schedule the training of its Exclusive Product Sales Specialists on The Wand® STA System. Specifically, nine Exclusive Product Sales Specialists have been fully trained and have become certified experts in the features, advantages and benefits of The Wand® STA. In addition, Henry Schein is on track to complete the training of an additional 16 Exclusive Product Sales Specialists before year-end. Henry Schein also plans to train an additional two to three dedicated customer service representatives to support dentists across the United States and Canada through its Inside Exclusives Sales Call Center.
The Wand® STA System is the market-leading computer-controlled local anesthesia system, with more than 60 million injections performed worldwide. The Wand® performs both traditional and newer dental anesthesia injections in a more effective and comfortable way for both the patient and the provider. The instrument utilizes patented technologies like computer-regulated flow rates, DPS Dynamic Pressure Sensing Technology®, and a uniquely ergonomic hand-piece to enable significant improvements over the traditional dental syringe and needle, which has remained virtually unchanged for over 160 years.
Gian Domenico Trombetta, CEO of Wand Dental, Inc. commented, "We are pleased with the progress Henry Schein has made since we began our exclusive distribution relationship. We anticipate that the training of Henry Schein's additional Exclusive Product Sales Specialists, Field Sales Consultants, and Inside Exclusives Call Center, combined with our broad marketing and distribution platform across the United States and Canada, will help further drive our dental instrument and handpiece business plan in 2017 and the coming years."
About Wand Dental, Inc.
Headquartered in Livingston, NJ, Wand Dental, Inc. is a wholly-owned subsidiary of Milestone Scientific Inc. and is engaged in the manufacture and sales of advanced computer-controlled drug delivery technologies to the global dental market. The company currently sells its award-winning products through a global distribution network serving North and South America, Asia, Africa, Europe and the Middle East.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Source: Milestone Scientific, Inc.
Released December 8, 2016